

Special Issue

Advances in the Treatment of Hepatocellular Carcinoma

Message from the Guest Editor

Hepatocellular carcinoma is the fourth leading cause of death, and long-term survival rates have yet to improve. However, the recent introduction of new molecularly targeted drugs and immune checkpoint inhibitors has changed the treatment of hepatocellular carcinoma. There are many topics to consider, such as the use of various drugs, the combination of molecular-targeted drugs and local therapy, surgery after drug therapy, and the relationship between hepatic reserve capacity and drug therapy. This Special Issue focuses on pharmacotherapy for hepatocellular carcinoma and welcomes all research that brings readers the latest information on pharmacotherapy for hepatocellular carcinoma, including drug therapy sequences that truly improve prognosis, combinations with local therapy and radiation therapy and conversion surgery, the microenvironment that governs immunity against hepatocellular carcinoma, and optimal drug therapy by reserve capacity and background factors.

Guest Editor

Dr. Rie Sugimoto

Department of Hepato-Biliary-Pancreatology, National Hospital Organization Kyushu Cancer Center, Fukuoka 8111395, Japan

Deadline for manuscript submissions

closed (1 March 2025)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/156430

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)